Heaf James G, Wehberg Sonja
Department of Nephrology B, Copenhagen University Hospital at Herlev, Herlev, Denmark.
Department of Epidemiology, Odense University Hospital, Odense, Denmark.
PLoS One. 2014 Mar 10;9(3):e90119. doi: 10.1371/journal.pone.0090119. eCollection 2014.
Epidemiological studies consistently show an initial survival advantage for PD patients compared to HD. It has recently been suggested that this is due to the fact that many HD patients are referred late, and start dialysis on an acute, in-patient basis. The present study was performed to investigate (1) whether, and if so, how, PD and HD prognosis had changed in recent years, (2) whether a potential survival advantage of PD versus HD is constant over dialysis duration, and (3) whether differences in prognosis could be explained by patient age, renal diagnosis of diabetic nephropathy, or mode of dialysis initiation.
12095 patients starting dialysis therapy between 1990 and 2010 in Denmark were studied. Prognosis was assessed according to initial dialysis modality on an intention-to-treat basis, censored for transplantation. Results were adjusted for age, sex, renal diagnosis, Charlson Comorbidity Index (CCI), and mode of dialysis initiation.
Overall adjusted prognosis improved by 34% (HD 30%, PD 42%). PD prognosis relative to HD improved, and was 16% better at the end of the period. Final PD prognosis improved consistently from 1990-99 to 2000-10 in all subgroups. PD was associated with a significant initial survival advantage, both overall and for all subgroups For the latter cohort, overall PD prognosis was better than HD for the first 4 years, after which it was insignificantly worse. The initial survival advantage was also present in a subgroup analysis of patients with early & routine ESRD initiation.
Dialysis survival has increased during the past 20 years. PD survival since 2000 has been better than HD, overall and for all subgroups. The difference in survival is not explained by mode of dialysis initiation.
流行病学研究一致表明,与血液透析(HD)患者相比,腹膜透析(PD)患者最初具有生存优势。最近有人提出,这是因为许多HD患者转诊较晚,且在急性住院的情况下开始透析。本研究旨在调查:(1)近年来PD和HD的预后是否发生了变化,如果发生了变化,是如何变化的;(2)PD相对于HD的潜在生存优势在透析期间是否恒定;(3)预后差异是否可以用患者年龄、糖尿病肾病的肾脏诊断或透析起始方式来解释。
对1990年至2010年间在丹麦开始透析治疗的12095例患者进行了研究。根据初始透析方式,在意向性治疗的基础上评估预后,并对移植进行删失处理。结果针对年龄、性别、肾脏诊断、Charlson合并症指数(CCI)和透析起始方式进行了调整。
总体调整后的预后改善了34%(HD改善30%,PD改善42%)。PD相对于HD的预后有所改善,在该时期结束时比HD好16%。从1990 - 1999年到2000 - 2010年,所有亚组的最终PD预后均持续改善。PD在总体和所有亚组中均具有显著的初始生存优势。对于后一组队列,在最初4年中,PD的总体预后优于HD,之后则略差但无统计学意义。在早期和常规开始终末期肾病(ESRD)的患者亚组分析中也存在初始生存优势。
在过去20年中,透析患者的生存率有所提高。自2000年以来PD的生存率在总体和所有亚组中均优于HD。生存差异无法用透析起始方式来解释。